| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to enantiomerically pure compound, represented by the following formula (I) or to its pharmaceutically acceptable salt where R1 represents phenyl, which is substituted with 2 different substituents selected from: halogen, fluoromethyl, difluoromethyl and trifluoromethyl, on condition that if one of substituents on phenyl group represents halogen, the other substituent is not halogen; R2 and R3 each is independently selected from: hydroxyl and OR8; where R8 represents substituted or unsubstituted C1-C10-alkyl, C1-C4-alkanoyl, substituted or unsubstituted aroyl; R4 represents C1-C4-alkylene hydroxyl; and R9 represents hydrogen or C1-C4-alkyl, to its enantiomerically pure intermediates, to methods of obtaining enantiomerically pure compound (I) and its intermediates, and to pharmaceutical composition, which includes enantiomerically pure compound of formula (I), as well as to application of formula (I) compound for manufacturing medication for cancer treatment. ^ EFFECT: obtained and described is novel enantiomerically pure compound, which can be usefull in treatment of diseases or disorders, mediated by inhibiting of cyclin-dependent kinase, for instance, cancer. ^ 9 cl, 98 ex, 2 tbl, 3 dwg |
